# Antibiotic stewardship benchmarking–Using the WHO point prevalence survey of antimicrobial prescribing in a Tertiary Care Public Hospital, Karachi

**Authors:** Ale Zehra, Tehreem Ansari, Syed Shaukat Ali Muttaqi Shah, Beenish Syed, Mehwish Rizvi, Fakhsheena Anjum, Tehrim Fatima, Farah Saeed, Mabel Aworh, Mabel Aworh, Mabel Aworh

PMC · DOI: 10.1371/journal.pone.0342985 · PLOS One · 2026-02-24

## TL;DR

This study assesses antibiotic use in a hospital in Karachi using WHO methods, finding high rates of antibiotic use and potential for improvement in stewardship practices.

## Contribution

The study benchmarks antibiotic prescribing in a public hospital in Karachi using WHO PPS methodology, revealing high empirical use and stewardship intervention opportunities.

## Key findings

- Antibiotic use prevalence was 83.3%, with 99.2% of prescriptions being empirical.
- Most antibiotics belonged to the WHO 'Watch' category, and 55.4% of prescriptions had stewardship intervention potential.
- Only 2.9% of patients had an intravenous-to-oral switch, indicating limited de-escalation practices.

## Abstract

Antimicrobial resistance (AMR) is a global threat, mainly linked to inappropriate use and prescription of antibiotics, Antimicrobial stewardship (AMS) programs have proved to promote responsible antibiotic use and decrease the burden of AMR. The aim of this study is to benchmark antibiotic prescribing patterns and evaluate stewardship practices using the World Health Organization (WHO) Point Prevalence Survey (PPS) methodology in a tertiary care public sector hospital in Karachi.

A cross-sectional, prospective PPS was conducted over four weeks in July 2024 at Dow University Hospital, Karachi. The data were extracted from the medical records of the patients using a validated WHO PPS tool by a trained infectious disease physician and pharmacist. All inpatients admitted before or at 8:00 a.m. on survey day, without a planned discharge were included, excluding those from emergency, acute care, day-care surgery, dialysis, and oncology units. Descriptive analysis of the data was performed using Stata version 14.

Out of 224 hospitalized patients at the day of survey, 186 inpatients (adults and children across medical, surgical and critical care wards) were included in the study meeting the inclusion criteria. The study included 50.5% male and 49.5% females, having mean age of 45 (±18) years. The point prevalence of antibiotic use was 83.3% (95% CI: 77.5–88.2%). Community-acquired infections 55.5% (95% CI: 48.7–62.1%) were the most common indication of use. Most antibiotics 99.2%, (95% CI: 95.6–99.9%) were prescribed empirically, with predominant parenteral administration 89.2% (95% CI: 84.5–92.9%) and limited Intravenous-to-oral switch 2.9% (95% CI: 1.3–6.2%). Ceftriaxone (18.5%), piperacillin-tazobactam (18.1%), and meropenem (16.2%) were most frequently used antibiotics. According to WHO Access, Watch and Reserve (AWaRe) classification, 80.8% (95% CI: 75.2–85.6%) of antibiotics belonged to the ‘Watch’ category, 17.3% (95% CI: 12.6–23.2%) to ‘Access’, and 1.8% (95% CI: 0.7–4.6%) to ‘Reserve’. Cultures showed no growth in 64.8% (95% CI: 55.2–73.6%) of cases. Stewardship interventions were found applicable in 55.4% (95% CI: 48.7–62.0%) of prescriptions due to overuse, dosing errors, and absence of antimicrobial guideline in the hospitals.

This study demonstrates that antibiotic utilization exceeded global averages, highlighting the urgent need to develop institutional antimicrobial guidelines, enhance stewardship programs, and improve diagnostic stewardship to curb AMR.

## Linked entities

- **Chemicals:** Ceftriaxone (PubChem CID 5479530), Piperacillin-tazobactam (PubChem CID 461573), Meropenem (PubChem CID 441130)

## Full-text entities

- **Genes:** SP1 (Sp1 transcription factor) [NCBI Gene 6667], SP2 (Sp2 transcription factor) [NCBI Gene 6668], SP3 (Sp3 transcription factor) [NCBI Gene 6670] {aka SPR2}, SH2D1A (SH2 domain containing 1A) [NCBI Gene 4068] {aka DSHP, EBVS, IMD5, LYP, MTCP1, SAP}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, SYNPR (synaptoporin) [NCBI Gene 132204] {aka SPO}, ASPM (assembly factor for spindle microtubules) [NCBI Gene 259266] {aka ASP, Calmbp1, MCPH5}, COL9A3 (collagen type IX alpha 3 chain) [NCBI Gene 1299] {aka DJ885L7.4.1, EDM3, IDD, MED, STL6}
- **Diseases:** MAJOR ISSUES (MESH:D004830), Hospital-Acquired Infection (MESH:D003428), blood infections (MESH:D000086982), AMR (MESH:D060467), infection (MESH:D007239), febrile (MESH:D000071072), Community Acquired infection (MESH:D017714), ID (MESH:D003141), MINOR (MESH:D004832)
- **Chemicals:** HDU (-), Clarithromycin (MESH:D017291), MP (MESH:C063925), amoxicillin/clavulanate (MESH:D019980), Piperacillin/tazobactam (MESH:D000077725), Ceftriaxone (MESH:D002443), Meropenem (MESH:D000077731), carbapenems (MESH:D015780), vancomycin (MESH:D014640), creatinine (MESH:D003404), beta-lactams (MESH:D047090)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606], Acinetobacter (genus) [taxon 469], Klebsiella pneumoniae (species) [taxon 573], Pseudomonas aeruginosa (species) [taxon 287], Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Mutations:** Q12H, Q24H, Q48H

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12931792/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12931792/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12931792/full.md

---
Source: https://tomesphere.com/paper/PMC12931792